Bristol-Myers Squibb

Yahoo Finance • 4 hours ago

Bristol Myers Squibb Stock Climbs on Alzheimer’s Trial Update. What to Know.

The drugmaker is testing its antipsychotic drug Cobenfy for the treatment of psychosis associated with Alzheimer’s disease. Continue Reading... Full story

Yahoo Finance • 6 hours ago

Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease

Study Continuation Follows Review of Site Level Data and Recommendation of Data Monitoring Committee BMS Remains Blinded to Study Data PRINCETON, N.J., December 03, 2025--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY, "BMS") today ann... Full story

Yahoo Finance • 11 hours ago

Cantor Fitzgerald Maintains Price Target on Bristol-Myers (BMY) Amid Milvexian Updates

Bristol-Myers Squibb Company (NYSE:BMY) ranks among the Best Low Volatility Investments in December 2025. Cantor Fitzgerald reaffirmed its Neutral rating and $45 price target on Bristol-Myers Squibb Company (NYSE:BMY) on November 24. Recen... Full story

Yahoo Finance • yesterday

FDA top drugs official Pazdur retiring shortly after starting - report

[Headquarters of US Food and Drug Administration (FDA)] Grandbrothers * Less than a month after taking the role, Richard Pazdur, the director of the US FDA's Center for Drug Evaluation and Research, has turned in his resignation papers,... Full story

Yahoo Finance • yesterday

US judge rules Bristol Myers faces $6.7B lawsuit over delayed cancer drug - report

A ‌U.S. judge on ‌Monday rejected Bristol Myers Squibb's (BMY [https://seekingalpha.com/symbol/BMY]) bid to dismiss a $6.7 ⁠billion lawsuit ‌claiming it cheated shareholders of the former ‍Celgene by delaying federal approval for three dru... Full story

Yahoo Finance • 2 days ago

UK to pay 25% more for new drugs under deal with US

[Pile of different colourful pills placed next to 20 British pound banknotes.] Oleksandr Siedov An agreement in principle reached between UK and US trade negotiators will have the latter's National Health Service pay 25% higher list price... Full story

Yahoo Finance • 2 days ago

Bristol Myers Squibb Unveils Positive Trial Data In Hematology Pipeline

(RTTNews) - Drug maker Bristol Myers Squibb Co. (BMY) announced Monday positive and promising data from the trials in Hematology pipeline, comprising Iberdomide, Golcadomide, BCL6 Degrader, as well as Breyanzi. The company announced the p... Full story

Yahoo Finance • 2 days ago

Bristol Myers Squibb Data at ASH 2025 Showcase Potential of Hematology Pipeline and Build Momentum for Next Generation Portfolio

Iberdomide shows deep and sustained responses in newly diagnosed multiple myeloma First-in-class lymphoma CELMoD™ agent, golcadomide, delivers durable responses in combinations across aggressive and indolent lymphomas First-in-class BCL6... Full story

Yahoo Finance • 3 days ago

BMY Gains Attention as Bayer Reports FXIa Trial Success

Bristol-Myers Squibb Company (NYSE:BMY) is included among the 15 Best Boring Dividend Stocks to Buy.BMY Gains Attention as Bayer Reports FXIa Trial Success Bayer repor⁠t​ed positive Phase‌ 3 result⁠s for its FXIa inhi‍bitor as​undexian, h... Full story

Yahoo Finance • 3 days ago

2 Top Dividend Stocks to Buy and Hold

Key Points Bristol Myers Squibb and Johnson & Johnson have had a tough past few years due to several factors. Both companies are looking to right the ship thanks to new product launches. These healthcare leaders routinely increase their... Full story

Yahoo Finance • 5 days ago

Bristol-Myers Squibb Surges 15% After Drug Approvals: Is the Stock a Bargain in 2025?

Wondering if Bristol-Myers Squibb is a bargain or overpriced? Let’s dig into what’s behind the numbers so you can decide with confidence. After a rocky start to the year, Bristol-Myers Squibb has staged an impressive rebound, gaining 15.6%... Full story

Yahoo Finance • 6 days ago

Bristol-Myers Squibb Company (BMY): A Bull Case Theory

We came across a bullish thesis on Bristol-Myers Squibb Company on CompoundingLab’s Substack. In this article, we will summarize the bulls’ thesis on BMY. Bristol-Myers Squibb Company's share was trading at $49 recently. BMY’s trailing and... Full story

Yahoo Finance • 6 days ago

Follicular Lymphoma Market Trends, Opportunities, Growth Challenges and Competitive Intelligence 2025-2035

Company Logo The global follicular lymphoma market is witnessing growth due to advancements in targeted therapies and immunotherapies. Follicular lymphoma, an indolent form of non-Hodgkin lymphoma, often presents challenges like relapse a... Full story

Yahoo Finance • 7 days ago

CMS unveils price reductions for 15 drugs for 2027

[Pills and money] txking/iStock via Getty Images Individuals covered under Medicare can expect significant savings on the 15 drugs that were selected earlier this year for drug price negotiations under the Inflation Reduction Act starting... Full story

Yahoo Finance • 7 days ago

Bristol Myers Squibb to Participate in Citi’s 2025 Global Healthcare Conference

PRINCETON, N.J., November 26, 2025--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in Citi’s 2025 Global Healthcare Conference on Thursday, December 4, 2025. The company will take part... Full story

Yahoo Finance • 8 days ago

A Fresh Look at Bristol-Myers Squibb (BMY) Valuation After Recent Share Price Rebound

Bristol-Myers Squibb (BMY) shares have seen mixed movement over the past month, with the stock rebounding nearly 9% but still trading below this year’s highs. Investors continue to monitor the company’s performance trends and financials.... Full story

Yahoo Finance • 8 days ago

US, UK nearing drug prices deal - report

[United States of America and United Kingdom Flags. 3d Rendering] klenger/iStock via Getty Images * The US and UK governments are said to be close to a deal that would boost prices of prescription drugs in the UK in exchange for avoidin... Full story

Yahoo Finance • 8 days ago

Top Healthcare revenue stocks as hedge funds sell Tech stocks to buy the sector

[3D charts graph with gift box, coin, analysis business financial data, online marketing isolated on pink background. business strategy minimal concept, 3d render illustration] warat42/iStock via Getty Images Goldman Sachs’ Tony Pasquarie... Full story

Yahoo Finance • 8 days ago

PD-1 Resistant Head and Neck Cancer Market Research Report 2025-2030: Cracking the Code of Immunotherapy Resistance - How Sox9 and Anxa1 Shape the Tumor-Immune Standoff

Dublin, Nov. 25, 2025 (GLOBE NEWSWIRE) -- The "PD-1 Resistant Head and Neck Cancer - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for PD-1 Resistant Head and Neck Can... Full story

Yahoo Finance • 9 days ago

Stocks Finish Sharply Higher as Tech Stocks Soar

The S&P 500 Index ($SPX) (SPY) on Monday closed up by +1.55%, the Dow Jones Industrials Index ($DOWI) (DIA) closed up by +0.44%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up by +2.62%.  December E-mini S&P futures (ESZ25) rose +1.56%,... Full story